Table 1 Clinical characterization of responders and non-responders to CRT
|  | Global Population Mean ± standard deviation (n = 39) | Responders Mean ± standard deviation (n = 21) | Non-Responders Mean ± standard deviation (n = 18) | P value Responders vs Non-responders |
|---|---|---|---|---|
Baseline assessment | ||||
 Gender (Male/Female) | 26 / 13 | 14 / 7 | 12 / 6 | 1 |
 Aetiology (Non-Ischemic/Ischemic) | 29 / 10 | 17 / 4 | 12 / 6 | 0.418 |
 NYHA (II/III/IV) | 8/ 27/ 4 | 4/ 16/ 1 | 4/ 11 /3 | 0.465 |
 LV lead position (L/PL/A/AL) | 17/11/3/8 | 12/4/2/3 | 5/7/1/5 | 0.228 |
 Age (years) | 61.4 ± 10.5 | 65.2 ± 9.6 | 56.9 ± 9.8 | 0.015 |
 LVEF (%) | 24.9 ± 6.9 | 23.8 ± 6.5 | 26.3 ± 7.4 | 0.309 |
 LVESV (mL) | 190.2 ± 84.9 | 180.1 ± 55.3 | 202.1 ± 111.0 | 0.903 |
 LVEDV (mL) | 244.2 ± 83.9 | 233.3 ± 58.9 | 257.1 ± 106.8 | 0.583 |
 QRS | 148.4 ± 30.6 | 144.5 ± 22.1 | 151.4 ± 36.6 | 0.866 |
 Total Leukocytes (× 103 µl) | 8.4 ± 1.7 | 8.1 ± 1.6 | 8.7 ± 1.8 | 0.242 |
 hsCRP (mg/L) | 5.6 ± 6.0 | 5.2 ± 5.1 | 5.9 ± 6.9 | 0.934 |
 BNP (pg/mL) | 362.8 ± 358.7 | 264.3 ± 214.8 | 461.3 ± 448.1 | 0.362 |
 Uric Acid (mg/dL) | 6.0 ± 1.7 | 5.6 ± 1.5 | 6.5 ± 1.9 | 0.231 |
 Cholesterol (mg/dL) | 185.9 ± 56.5 | 194.47 ± 61.85 | 175,81 ± 49.55 | 0.466 |
 HDL Cholesterol (mg/dL) | 44.4 ± 11.7 | 48.53 ± 11.04 | 39,56 ± 10.84 | 0.031 |
 LDL Cholesterol (mg/dL) | 117.4 ± 46.3 | 121.47 ± 49.98 | 111,41 ± 42.33 | 0.499 |
 Triglycerides (mg/dL) | 132.8 ± 55.2 | 122.37 ± 50.20 | 146.00 ± 59.68 | 0.252 |
After CRT | ||||
 Total Leukocytes (× 103 µl) | 8.3 ± 1.8 | 8.1 ± 1.5 | 8.6 ± 2.1 | 0.220 |
 LVEF (%) | 33.9 ± 10.8 | 39.1 ± 9.8 | 27.6 ± 8.4 | 0.001 |
 LVESV (mL) | 151.4 ± 96.0 | 100.4 ± 36.7 | 215.1 ± 109.6 |  < 0.001 |
 LVEDV (mL) | 220.2 ± 108.5 | 168.9 ± 50.3 | 284.4 ± 127.9 | 0.001 |
 hsCRP (mg/L) | 4.1 ± 4.6 | 2.6 ± 1.8 | 6.2 ± 6.4 | 0.288 |
 BNP (pg/mL) | 245.3 ± 334.6 | 139.6 ± 164.1 | 403.9 ± 456.0 | 0.043 |